[go: up one dir, main page]

EA201101188A1 - [1,2,4]триазоло[1,5-а]пиридины в качестве ингибиторов киназы - Google Patents

[1,2,4]триазоло[1,5-а]пиридины в качестве ингибиторов киназы

Info

Publication number
EA201101188A1
EA201101188A1 EA201101188A EA201101188A EA201101188A1 EA 201101188 A1 EA201101188 A1 EA 201101188A1 EA 201101188 A EA201101188 A EA 201101188A EA 201101188 A EA201101188 A EA 201101188A EA 201101188 A1 EA201101188 A1 EA 201101188A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
kinase
symptoms
mediated disorder
relates
Prior art date
Application number
EA201101188A
Other languages
English (en)
Inventor
Каролине Лериш
Эрик Оклер
Жак Ле Ру
Дейвид Миддлмисс
Original Assignee
Фовеа Фармасьютикалз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42229029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201101188(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фовеа Фармасьютикалз filed Critical Фовеа Фармасьютикалз
Publication of EA201101188A1 publication Critical patent/EA201101188A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретение относится к определенным новым соединениям, способам их получения и способам лечения или уменьшения симптомов нарушения, опосредованного киназой. Более предпочтительно настоящее изобретение относится к замещенным триазолопиридиновым соединениям, пригодным в качестве селективных ингибиторов киназы, способам получения таких соединений и способам лечения или уменьшения симптомов нарушения, опосредованного киназой. В частности, способ относится к лечению или уменьшению симптомов нарушения, опосредованного киназой, включая сердечно-сосудистые заболевания, диабет, нарушения, связанные с диабетом, воспалительные заболевания, иммунологические нарушения, злокачественное новообразование и заболевания глаз, такие как ретинопатии или дегенерация желтого пятна или другие витреоретинальные заболевания, и другие.
EA201101188A 2009-02-13 2010-02-09 [1,2,4]триазоло[1,5-а]пиридины в качестве ингибиторов киназы EA201101188A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09360013 2009-02-13
PCT/EP2010/051556 WO2010092041A1 (en) 2009-02-13 2010-02-09 [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
EA201101188A1 true EA201101188A1 (ru) 2012-04-30

Family

ID=42229029

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101188A EA201101188A1 (ru) 2009-02-13 2010-02-09 [1,2,4]триазоло[1,5-а]пиридины в качестве ингибиторов киназы

Country Status (24)

Country Link
US (1) US20120041195A1 (ru)
EP (1) EP2396324A1 (ru)
JP (1) JP2012517971A (ru)
KR (1) KR20110116160A (ru)
CN (1) CN102317288A (ru)
AR (1) AR075411A1 (ru)
BR (1) BRPI1008850A2 (ru)
CA (1) CA2751517A1 (ru)
CL (1) CL2011001947A1 (ru)
CO (1) CO6420343A2 (ru)
CR (1) CR20110386A (ru)
DO (1) DOP2011000248A (ru)
EA (1) EA201101188A1 (ru)
EC (1) ECSP11011250A (ru)
HN (1) HN2011002095A (ru)
IL (1) IL214426A0 (ru)
MX (1) MX2011008549A (ru)
NI (1) NI201100151A (ru)
NZ (1) NZ594508A (ru)
PE (1) PE20120110A1 (ru)
SG (1) SG173610A1 (ru)
TN (1) TN2011000379A1 (ru)
WO (1) WO2010092041A1 (ru)
ZA (1) ZA201105896B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141796A2 (en) 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
AR081960A1 (es) * 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
EP2699575B1 (en) 2011-04-21 2015-03-25 Bayer Intellectual Property GmbH Triazolopyridines
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
KR20130091464A (ko) 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
WO2013135612A1 (en) 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
WO2014009219A1 (en) 2012-07-10 2014-01-16 Bayer Pharma Aktiengesellschaft Method for preparing substituted triazolopyridines
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
EP3008062B1 (en) 2013-06-11 2017-04-05 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
WO2021098813A1 (zh) * 2019-11-22 2021-05-27 南京明德新药研发有限公司 作为dna-pk抑制剂的嘧啶并吡咯类螺环化合物及其衍生物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4271143A (en) 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
DE3486448T2 (de) 1983-11-14 1997-10-09 Columbia Lab Inc Bioadhäsive Mittel
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
AU1462101A (en) 1999-11-22 2001-06-04 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
AU2003297161B8 (en) * 2002-12-18 2011-03-31 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
ATE433967T1 (de) 2003-01-17 2009-07-15 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CA2542329A1 (en) 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
EP1799656A4 (en) 2004-08-25 2009-09-02 Targegen Inc HETEROCYCLIC COMPOUNDS AND METHODS OF USE
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CN101155799A (zh) 2005-03-16 2008-04-02 塔格根公司 嘧啶化合物和使用方法
EP1878727A4 (en) 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
US20060292203A1 (en) 2005-06-08 2006-12-28 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
JP2009531274A (ja) * 2005-12-07 2009-09-03 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド キナーゼ阻害性ピロロピリジン化合物
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
JP5336375B2 (ja) * 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
KR101079520B1 (ko) * 2006-10-20 2011-11-03 아이알엠 엘엘씨 Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 수용체를 조절하기 위한 조성물 및 방법
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
KR20090092287A (ko) 2006-12-22 2009-08-31 노파르티스 아게 Ｐｄｋ１ 억제를 위한 퀴나졸린
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20100035875A1 (en) * 2008-06-20 2010-02-11 Bing-Yan Zhu Triazolopyridine jak inhibitor compounds and methods
US20100048557A1 (en) * 2008-06-20 2010-02-25 Bing-Yan Zhu Triazolopyridine JAK Inhibitor Compounds and Methods
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010188A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010189A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
EP2323978A1 (en) * 2008-08-12 2011-05-25 Takeda Pharmaceutical Company Limited Amide compound
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法

Also Published As

Publication number Publication date
PE20120110A1 (es) 2012-02-20
SG173610A1 (en) 2011-09-29
JP2012517971A (ja) 2012-08-09
HN2011002095A (es) 2014-01-06
DOP2011000248A (es) 2011-10-31
CO6420343A2 (es) 2012-04-16
MX2011008549A (es) 2011-12-06
CA2751517A1 (en) 2010-08-19
ZA201105896B (en) 2012-03-28
CR20110386A (es) 2011-12-02
CN102317288A (zh) 2012-01-11
US20120041195A1 (en) 2012-02-16
WO2010092041A1 (en) 2010-08-19
NZ594508A (en) 2013-12-20
EP2396324A1 (en) 2011-12-21
CL2011001947A1 (es) 2012-03-16
KR20110116160A (ko) 2011-10-25
BRPI1008850A2 (pt) 2016-03-15
TN2011000379A1 (en) 2013-03-27
NI201100151A (es) 2012-10-03
AR075411A1 (es) 2011-03-30
ECSP11011250A (es) 2011-10-31
IL214426A0 (en) 2011-09-27

Similar Documents

Publication Publication Date Title
EA201101188A1 (ru) [1,2,4]триазоло[1,5-а]пиридины в качестве ингибиторов киназы
EA201590870A1 (ru) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ
EA201690998A1 (ru) НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
EA201390971A1 (ru) ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
EP4249076A3 (en) (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor
NZ605022A (en) Heterocyclic compounds, their preparation and their therapeutic application
EA201101012A1 (ru) Замещенные хиназолиновые соединения
EA201300556A1 (ru) Аминоспиртзамещенные производные 2,3-дигидроимидазо[1,2-с] хиназолина, пригодные для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
CL2007001165A1 (es) 2-(1h-indazol-4-il)-6-(4-metanosulfonil-piperazin-1-ilmetil)-4-morfolin-4-il-tieno[3,2-d]pirimidina; procedimiento de preparacion; composicion farmaceutica; proceso de preparacion de dicha composicion; kit farmaceutico; y uso para tratar enfermedades tales como cancer, desordenes inmunes y enfermedades cardiovasculares.
EA201391416A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
EA201891374A1 (ru) Замещенные 2-фенил-3-(пиперазинметил)имидазопиридины и их применение
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
WO2010005558A3 (en) Pi3k isoform selective inhibitors
WO2012174487A8 (en) Bromodomain inhibitors and uses thereof
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
MX355852B (es) Compuestos de pirazolo [3,4-c] piridina y métodos de uso.
EA201400392A1 (ru) ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
EA201590663A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
EA201290878A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ, ПСИХИАТРИЧЕСКИХ И МЕТАБОЛИЧЕСКИХ РАССТРОЙСТВ И ЗАБОЛЕВАНИЙ
WO2007120752A3 (en) 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders
PE20141023A1 (es) Derivados de (1,2,4) triazolo [4,3-a] quinoxalina como inhibidores de fosfodiesterasas
NZ629499A (en) Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases